Helping The others Realize The Advantages Of Antidepressant agent 5
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Major demo aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients,